These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37976066)

  • 1. Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer.
    Jarnagin JX; Saraf A; Baiev I; Chi G; van Seventer EE; Mojtahed A; Allen JN; Clark JW; Blaszkowsky L; Giantonio BJ; Weekes CD; Klempner SJ; Franses JW; Roeland EJ; Goyal L; Siravegna G; Horick N; Corcoran RB; Nipp RD; Parikh AR
    JAMA Netw Open; 2023 Nov; 6(11):e2343512. PubMed ID: 37976066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer.
    van Seventer EE; Fish MG; Fosbenner K; Kanter K; Mojtahed A; Allen JN; Blaszkowsky L; Clark JW; Dubois J; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Roeland EJ; Ryan DP; Weekes CD; Mulvey T; El-Jawahri A; Horick N; Corcoran RB; Parikh AR; Nipp RD
    Cancer; 2021 Feb; 127(4):619-627. PubMed ID: 33170962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of patient-reported care satisfaction with symptom burden and healthcare use in hospitalized patients with cancer.
    Qian CL; Kaslow-Zieve ER; Azoba CC; Horick N; Wang I; Van Seventer E; Newcomb R; Cashavelly BJ; Jackson VA; Ryan DP; Greer JA; El-Jawahri A; Temel JS; Nipp RD
    Support Care Cancer; 2022 May; 30(5):4527-4536. PubMed ID: 35112210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Tjong MC; Doherty M; Tan H; Chan WC; Zhao H; Hallet J; Darling G; Kidane B; Wright FC; Mahar A; Davis LE; Delibasic V; Parmar A; Mittmann N; Coburn NG; Louie AV
    Oncologist; 2021 Oct; 26(10):e1800-e1811. PubMed ID: 34216415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.
    Hsu T; Speers CH; Kennecke HF; Cheung WY
    Cancer; 2017 May; 123(10):1839-1847. PubMed ID: 28081292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with patient-reported subjective well-being among advanced lung or non-colonic gastrointestinal cancer patients.
    Yennurajalingam S; Kim YJ; Zhang Y; Park J; Arthur J; Chisholm GB; Williams JL; Bruera E
    Palliat Support Care; 2018 Feb; 16(1):23-31. PubMed ID: 28264748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
    Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
    Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient- vs Physician-Initiated Response to Symptom Monitoring and Health-Related Quality of Life: The SYMPRO-Lung Cluster Randomized Trial.
    Billingy NE; van den Hurk CJG; N M F Tromp V; van de Poll-Franse L; Onwuteaka-Philipsen BD; Hugtenburg JG; Bogaard HJ; Belderbos J; Aaronson NK; Walraven I; Becker-Commissaris A;
    JAMA Netw Open; 2024 Aug; 7(8):e2428975. PubMed ID: 39186274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Oliveira M; Rugo HS; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Toi M; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Nowecki Z; Park YH; Sohn JH; Tokunaga E; Yousef S; Zhukova L; Fulford M; Andrews H; Wadsworth I; D'Cruz C; Turner NC;
    Lancet Oncol; 2024 Sep; 25(9):1231-1244. PubMed ID: 39214106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial.
    Manz CR; Schriver E; Ferrell WJ; Williamson J; Wakim J; Khan N; Kopinsky M; Balachandran M; Chen J; Patel MS; Takvorian SU; Shulman LN; Bekelman JE; Barnett IJ; Parikh RB
    J Med Internet Res; 2024 May; 26():e51059. PubMed ID: 38758583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma.
    Wang Y; Zheng D; Chen T; Zhang J; Yao F; Chen H
    Ann Thorac Surg; 2020 Mar; 109(3):927-937. PubMed ID: 31614135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
    Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
    Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMART-ESAS: Smartphone Monitoring and Assessment in Real Time of Edmonton Symptom Assessment System Scores for Patients With Cancer.
    Nagpal C; Sharma A; Bakhshi S; Malik PS; Gupta H; Mittal C; Gund S; Kumar A; Sharma A; Pushpam D; Khurana S; Pramanik R; Gupta N; Batra A
    JCO Glob Oncol; 2024 Feb; 10():e2300447. PubMed ID: 38386957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy.
    Turner K; Brownstein NC; Thompson Z; El Naqa I; Luo Y; Jim HSL; Rollison DE; Howard R; Zeng D; Rosenberg SA; Perez B; Saltos A; Oswald LB; Gonzalez BD; Islam JY; Tabriz AA; Zhang W; Dilling TJ
    Radiother Oncol; 2022 Feb; 167():116-121. PubMed ID: 34953934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer: A Randomized Clinical Trial.
    Nipp RD; Horick NK; Qian CL; Knight HP; Kaslow-Zieve ER; Azoba CC; Elyze M; Landay SL; Kay PS; Ryan DP; Jackson VA; Greer JA; El-Jawahri A; Temel JS
    JAMA Oncol; 2022 Apr; 8(4):571-578. PubMed ID: 35142814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
    Baumrin E; Shin DB; Mitra N; Pidala J; El Jurdi N; Lee SJ; Loren AW; Gelfand JM
    JAMA Dermatol; 2024 Apr; 160(4):393-401. PubMed ID: 38416506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.